Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan’s Prescription Dispensing Costs Increase Six Percent

This article was originally published in PharmAsia News

Executive Summary

Japan's Central Social Insurance Council summarized July 16 electronic receipts of dispensing medical fees for fiscal year 2007.The average medical cost per prescription is ¥7,322, an increase of 5.8 percent compared to previous year. Among the two sections, cost of drugs increased by 7.5 percent to ¥5,387, compared to 1.2 percent increase in technical fees. The cost of drugs directly contributed to the medical cost increases, especially for cardiovascular treatments, which cost ¥1,360 per prescription, a 7.9 percent increase. Hypertension drugs increased 10.9 percent and followed by hyperlipidemia drugs, which increased 8.9 percent. (Click here for more - Japanese language) "Prescription Dispensing Cost Increase Nearly 6 Percent, Reported By Electronic Receipts" - Yakuji News (7/17/08)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069084

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel